Welcome to our dedicated page for scPharmaceuticals news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on scPharmaceuticals stock.
scPharmaceuticals Inc. (NASDAQ: SCPH) is a clinical-stage pharmaceutical company dedicated to revolutionizing the administration of infused therapies. Headquartered in Burlington, MA, the company is spearheading advancements in patient care through its proprietary platform that enables subcutaneous administration of treatments traditionally limited to intravenous (IV) delivery. This innovative approach aims not only to improve patient outcomes but also to significantly reduce healthcare costs.
The company’s flagship product, Furoscix, is a patented furosemide formulation designed for subcutaneous use via the wearable, portable sc2Wear Infusor. Furoscix targets the treatment of edema in heart failure patients, offering them a convenient and effective alternative to traditional IV therapies. With a focus on self-administration, scPharmaceuticals is paving the way for outpatient care of acute conditions.
Recent achievements have bolstered scPharmaceuticals’ position in the pharmaceutical landscape. The company generated $6.1 million in product revenue for the first quarter of 2024, a marked increase from $2.1 million in the same period of the previous year. This growth reflects the rising demand for Furoscix and the successful execution of their commercial strategy.
Moreover, scPharmaceuticals is actively pursuing long-term growth initiatives for Furoscix. These include expanding its indication to include NYHA Class IV heart failure patients and chronic kidney disease, both pending FDA review. Another promising development is the initiation of a pharmacokinetic study to support a low-volume auto-injector version of Furoscix, aimed at providing greater flexibility in treatment options.
The company’s financial health remains robust, with strategic investments in research and development, as well as selling, general, and administrative expenses to support its growth trajectory. Despite reporting a net loss of $14.1 million for the first quarter of 2024, compared to $11.2 million for the first quarter of 2023, scPharmaceuticals remains focused on driving forward with its innovative solutions and strategic partnerships.
For more information, please visit www.scPharmaceuticals.com.
scPharmaceuticals Inc. (Nasdaq: SCPH) has announced a proposed underwritten public offering of shares of its common stock and pre-funded warrants. The company, focused on optimizing infused therapies delivery, aims to advance patient care and reduce healthcare costs. Leerink Partners and TD Cowen are acting as joint book-running managers for the offering.
The offering includes:
- Common stock shares
- Pre-funded warrants to purchase shares
- 30-day option for underwriters to purchase up to 15% additional shares
The offering is subject to market conditions, with no assurance of completion or final terms. It is being made pursuant to a shelf registration statement on Form S-3, filed with the SEC on March 13, 2024, and declared effective on March 22, 2024.
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on optimizing infused therapy delivery, will announce its second quarter 2024 financial results on Wednesday, August 14, 2024. The company's management will host a conference call and audio webcast at 4:30 p.m. ET to discuss the financial results and provide a business update.
Participants can join the call by dialing 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13747259. A new Call me™ feature is available to avoid operator wait times. The live webcast and replay can be accessed through the company's website under the Investor Relations section.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that the FDA has accepted their Supplemental New Drug Application (sNDA) to expand FUROSCIX indication to include treatment of edema due to fluid overload in patients with chronic kidney disease (CKD). The FDA has set a PDUFA target action date of March 6, 2025.
Key points:
- No additional clinical studies needed for indication expansion
- CKD affects more than 1 in 7 U.S. adults
- Estimated $3 billion addressable market
- Company preparing to deploy additional commercial resources if sNDA is approved
FUROSCIX is currently indicated for treating congestion due to fluid overload in adult patients with NYHA Class II and III chronic heart failure.
scPharmaceuticals (Nasdaq: SCPH) announced that its CEO, John Tucker, will present at the Jefferies Global Healthcare Conference on June 5, 2024. The presentation will occur at 5:00 PM ET, with Tucker also engaging in meetings with investors throughout the day. The webcast of the presentation will be accessible via the company’s Investor Relations section on its website.
scPharmaceuticals (SCPH) reported first quarter 2024 financial results, with notable achievements in FUROSCIX®. The company generated $6.1 million in net FUROSCIX revenue, despite a 10% dose impact from the Change Healthcare cyberattack. There was a 28% increase in total doses written and a 15% rise in doses filled compared to Q4 2023. The company ended Q1 with $58.4 million in cash and equivalents. Key developments include enrolling the first patient in a PK study for an 80mg/1mL auto-injector and submitting a sNDA to expand FUROSCIX's indication to NYHA Class IV heart failure patients, with a PDUFA date set for August 2024. However, scPharmaceuticals reported a net loss of $14.1 million for the quarter, with increased R&D and SG&A expenses.
scPharmaceuticals (Nasdaq: SCPH) will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ World Headquarters in New York on May 20, 2024, at 11:00AM ET.
John Tucker, President & CEO, will present and meet with investors. The company's focus is on developing and commercializing products to optimize the delivery of infused therapies, improve patient care, and reduce healthcare costs. The presentation will be webcast and available in the Investor Relations section of the company's website.
scPharmaceuticals Inc. will announce its first-quarter 2024 financial results on Tuesday, May 14, 2024. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a business update. Participants can access the call by dialing 1-800-717-1738 (domestic) or 1-646-307-1865 (international) with the conference code 89054. The webcast and replay will be available on the Investor Relations section of the company's website.
FAQ
What is the current stock price of scPharmaceuticals (SCPH)?
What is the market cap of scPharmaceuticals (SCPH)?
What is scPharmaceuticals Inc.?
What is Furoscix?
Where is scPharmaceuticals headquartered?
How much revenue did scPharmaceuticals generate in Q1 2024?
What are the future plans for Furoscix?
What are the benefits of scPharmaceuticals' platform?
What recent financial results did scPharmaceuticals report?
What is the sc2Wear Infusor?
Who are the key contacts for more information?
What is scPharmaceuticals' approach to outpatient care?
